BeyondSpring (NASDAQ:BYSI) Given News Impact Score of 0.03

News stories about BeyondSpring (NASDAQ:BYSI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BeyondSpring earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.6141036134316 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern’s scoring:

BeyondSpring (BYSI) traded up 6.66% during midday trading on Friday, reaching $40.97. The company had a trading volume of 1,797 shares. The company’s market capitalization is $889.34 million. BeyondSpring has a one year low of $16.55 and a one year high of $48.49. The stock’s 50 day moving average is $40.60 and its 200 day moving average is $31.34.

BYSI has been the topic of a number of recent analyst reports. Rodman & Renshaw boosted their target price on BeyondSpring from $43.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, July 14th. HC Wainwright set a $43.00 target price on BeyondSpring and gave the company a “buy” rating in a research note on Wednesday, May 31st. Finally, Zacks Investment Research raised BeyondSpring from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st.

COPYRIGHT VIOLATION WARNING: “BeyondSpring (NASDAQ:BYSI) Given News Impact Score of 0.03” was published by Rincon Hill News and is the property of of Rincon Hill News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with our FREE daily email newsletter.


Latest News

Leave a Reply

© 2006-2017 Rincon Hill News.